SG10201700916SA - Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof - Google Patents

Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Info

Publication number
SG10201700916SA
SG10201700916SA SG10201700916SA SG10201700916SA SG10201700916SA SG 10201700916S A SG10201700916S A SG 10201700916SA SG 10201700916S A SG10201700916S A SG 10201700916SA SG 10201700916S A SG10201700916S A SG 10201700916SA SG 10201700916S A SG10201700916S A SG 10201700916SA
Authority
SG
Singapore
Prior art keywords
listerial
expression
preparation
methods
signal peptide
Prior art date
Application number
SG10201700916SA
Other languages
English (en)
Inventor
Peter M Lauer
William G Hanson
Justin Skoble
Meredith Lai Ling Leong
Marcella Fasso
Dirk Brockstedt
Thomas W Dubensky Jr
Original Assignee
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Inc filed Critical Aduro Biotech Inc
Publication of SG10201700916SA publication Critical patent/SG10201700916SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Physics & Mathematics (AREA)
SG10201700916SA 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof SG10201700916SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746237P 2012-12-27 2012-12-27
US201361780744P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
SG10201700916SA true SG10201700916SA (en) 2017-03-30

Family

ID=51017446

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201700916SA SG10201700916SA (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
SG11201502792TA SG11201502792TA (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201502792TA SG11201502792TA (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Country Status (12)

Country Link
US (2) US9663557B2 (enExample)
EP (1) EP2938627B1 (enExample)
JP (2) JP2016503655A (enExample)
KR (1) KR102160322B1 (enExample)
CN (1) CN104955835B (enExample)
AU (2) AU2013370210B2 (enExample)
BR (1) BR112015015076A2 (enExample)
CA (1) CA2888727A1 (enExample)
EA (1) EA201590397A8 (enExample)
MX (1) MX2015008329A (enExample)
SG (2) SG10201700916SA (enExample)
WO (1) WO2014106123A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
WO2009143167A2 (en) 2008-05-19 2009-11-26 Advaxis Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP2621527A4 (en) 2010-10-01 2015-12-09 Univ Pennsylvania USE OF LISTERIA VACCINE VECTORS TO REVERSE VACCINE IMMUNITY IN PATIENTS WITH PARASITIC INFECTIONS
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
MX2014011061A (es) 2012-03-12 2016-09-29 Advaxis Inc Inhibicion de funcion de celula supresora despues de tratamiento con vacuna listeria.
US9907849B2 (en) 2014-07-18 2018-03-06 Advaxis, Inc. Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
SG11201706236SA (en) * 2015-02-06 2017-08-30 Nat Univ Singapore Methods for enhancing efficacy of therapeutic immune cells
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
US9808516B2 (en) * 2015-04-13 2017-11-07 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
HK1250730A1 (zh) * 2015-04-13 2019-01-11 艾杜罗生物科技公司 表皮生长因子受体变体iii-间皮素融合物及其使用方法
EP3298031B1 (en) * 2015-05-18 2020-10-21 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
EP4299136A3 (en) 2015-12-16 2024-02-14 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
MA43827A (fr) * 2016-03-18 2018-11-28 Immune Sensor Llc Composés di-nucléotides cycliques et leurs procédés d'utilisation
JP7778468B2 (ja) 2016-11-22 2025-12-02 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断
JP2020530291A (ja) 2017-08-10 2020-10-22 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞受容体欠損キメラ抗原受容体ｔ細胞およびその使用方法
CN111356760A (zh) 2017-09-19 2020-06-30 阿德瓦希斯公司 细菌或李斯特菌菌株的冻干组合物和方法
EP3694532B1 (en) 2017-10-10 2025-02-26 Gritstone bio, Inc. Neoantigen identification using hotspots
IL274799B2 (en) 2017-11-22 2025-05-01 Gritstone Bio Inc Reducing junction epitope presentation for neoantigens
EP3536706A1 (en) 2018-03-09 2019-09-11 BiOMVis Srl Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof
CN112074737A (zh) 2018-03-09 2020-12-11 阿德瓦希斯公司 用于评估李斯特菌菌株的减毒和感染性的组合物和方法
WO2019210034A1 (en) 2018-04-27 2019-10-31 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
CN110408634B (zh) 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
EP3784776A4 (en) 2018-05-23 2022-01-26 National University of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
EP3725371A1 (en) 2019-04-18 2020-10-21 BiOMVis Srl Method for the production of outer membrane vesicles and immunogenic compositions thereof
CN110499324A (zh) * 2019-09-02 2019-11-26 中生康元生物科技(北京)有限公司 一种用于鉴定肿瘤新抗原的细菌表达载体及筛选鉴定肿瘤新抗原的方法
CN116096920A (zh) 2020-06-23 2023-05-09 科罗拉多大学董事会法人团体 用于诊断呼吸道病原体和预测covid-19相关结果的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US7635479B2 (en) * 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
EP1320602A2 (en) 2000-09-21 2003-06-25 The Regents Of The University Of California Spas-1 cancer antigen
CA2486980A1 (en) 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
JP2007509067A (ja) 2003-10-15 2007-04-12 メディミューン，インコーポレーテッド リステリアに基づくＥｐｈＡ２ワクチン
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US7858097B2 (en) * 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
ES2532942T3 (es) * 2006-03-01 2015-04-06 Aduro Biotech Listeria obtenida por ingeniería genética y métodos de uso de la misma
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US20080124354A1 (en) 2006-07-10 2008-05-29 Yvonne Paterson Methods for administering tumor vaccines
JP2010534058A (ja) * 2007-04-16 2010-11-04 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性のないリステリア菌およびその構築および使用方法
EP2283112B1 (en) 2008-05-19 2016-10-12 Aduro Biotech Compositions comprising prfa*mutant listeria and methods of use thereof
GB201010389D0 (en) 2010-06-21 2010-08-04 Ist Superiore Sanita Antibody derivatives
ES2684684T3 (es) 2010-11-17 2018-10-04 Aduro Biotech, Inc. Métodos y composiciones para inducir una respuesta inmune al EGFRVIII
CA2829960A1 (en) * 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
MX2014011061A (es) 2012-03-12 2016-09-29 Advaxis Inc Inhibicion de funcion de celula supresora despues de tratamiento con vacuna listeria.

Also Published As

Publication number Publication date
US9663557B2 (en) 2017-05-30
US20170253637A1 (en) 2017-09-07
AU2013370210B2 (en) 2018-06-14
EP2938627A1 (en) 2015-11-04
US20140186387A1 (en) 2014-07-03
EA201590397A1 (ru) 2016-02-29
EA201590397A8 (ru) 2016-08-31
WO2014106123A8 (en) 2016-06-16
JP6671408B2 (ja) 2020-03-25
AU2013370210A1 (en) 2015-06-18
KR20150099738A (ko) 2015-09-01
CA2888727A1 (en) 2014-07-03
AU2018203555A1 (en) 2018-06-07
EP2938627A4 (en) 2016-12-14
CN104955835B (zh) 2020-04-17
CN104955835A (zh) 2015-09-30
JP2018135355A (ja) 2018-08-30
HK1215260A1 (zh) 2016-08-19
BR112015015076A2 (pt) 2018-10-30
SG11201502792TA (en) 2015-05-28
KR102160322B1 (ko) 2020-09-25
EP2938627B1 (en) 2019-03-20
AU2013370210A8 (en) 2016-06-23
WO2014106123A1 (en) 2014-07-03
MX2015008329A (es) 2016-03-01
JP2016503655A (ja) 2016-02-08

Similar Documents

Publication Publication Date Title
SG10201700916SA (en) Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
ZA201502991B (en) Disubstituted amino acids and methods of preparation and use thereof
ZA201404962B (en) Modified mini-hepcidin peptides and methods of using thereof
EP2874642A4 (en) Anti-inflammatory proteins and peptides, and methods for their preparation and use
IL241787B (en) Human fcrn-binding modified antibodies and methods of their use
PT2945647T (pt) Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
SI2581389T1 (sl) Fuzijski protein eksendina-4 in njegov analog, metoda priprave in njena uporaba
PT3744835T (pt) Proteínas de fusão modificadoras do adn e métodos de utilização das mesmas
SG10201811256QA (en) Serpin fusion polypeptides and methods of use thereof
ZA201404712B (en) Composite antigenic sequences and vaccines
PL2895512T3 (pl) Przeciwciała swoiste dla polipeptydu amyloidowego ludzkich wysepek (HIAPP) i ich zastosowania
EP3029072A4 (en) Glp-1 analog fusion protein and preparation method and use thereof
IL233481A0 (en) Peptides and methods of using them
IL241418A0 (en) Improved methods of use for recombinant human secretoglobins
HUS2200014I1 (hu) Hosszan ható polipeptidek és eljárás azok elõállítására és beadására
EP2996718A4 (en) E1e2 hcv vaccines and methods of use
EP3078677A4 (en) Antigen chimera, antigen combination, vaccine, method of preparing same, and kit thereof
GB2503388B (en) Sealing ring and preparation method thereof
SG10201506857QA (en) Method of synthesizing peptides, proteins and bioconjugates
IL239671A0 (en) Stable form of fusion proteins of signal transducing protein, and methods for their use and preparation
IL245273A0 (en) Long-acting polypeptides and methods for their preparation and administration
IL237719A0 (en) Antibodies specific to (hiapp) human islet amylid polypeptide and their uses